Procoagulant phenotype of endothelial cells after coculture with biomaterial‐treated blood cells
Source abstract
Abstract
Abstract Understanding endothelial cell (EC)/blood/biomaterial interactions is crucial for the advancement of cardiovascular devices that often fail because of the lack of nonthrombogenic biomaterials. To begin to assess these interactions, a static EC/blood cell/biomaterial model was used. Isolated blood cells were pretreated with model biomaterial beads with different surface chemistries: polystyrene (PS), and PS beads grafted with 3‐kDa polyethylene glycol (PEG) with either a hydroxyl (PS‐PEG‐OH) or amine (PS‐PEG‐NH2) terminal group at 5.4 or 54 × 104 beads/mL. Biomaterial‐treated monocytes, neutrophils, or platelets were applied to human umbilical vein ECs (HUVECs) for 5 or 24 h of static coculture, and the resultant procoagulant HUVEC phenotype was characterized using several methods. Flow cytometry was used to assess surface expression of tissue factor (TF), adenosine triphosphate diphosphohydrolase, phosphatidylserine, and thrombomodulin, a functional TF assay was used to assess TF activity, and a plasma recalcification assay examined clotting times on HUVECs. Static coculture of HUVEC with biomaterial‐treated neutrophils induced a procoagulant phenotype as exemplified by upregulation of TF expression and total functional activity, and downregulation of adenosine triphosphate diphosphohydrolase and thrombomodulin expression. The plasma recalcification assay demonstrated that HUVECs cocultured with biomaterial‐treated monocytes significantly shortened clotting times, with some effect of similarly treated neutrophils. © 2005 Wiley Periodicals, Inc. J Biomed Mater Res 72A: 269–278, 2005
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Electrospun Nanofibers in Biomedical Applications · Tissue Engineering and Regenerative Medicine · Tracheal and airway disorders
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (38)
Show source-provided references
1. 10.1243/095441198153422210.1243/0954411981534222 ↗
2. 10.1038/nbt0695-56510.1038/nbt0695-565 ↗
3. 10.1002/1097-4636(20010615)55:4<447::AID-JBM1036>3.0.CO;2-510.1002/1097-4636(20010615)55:4<447::AID-JBM1036>3.0.CO;2-5 ↗
4. A single staged technique for seeding vascular grafts with autogenous endothelium
5. 10.1126/science.849352910.1126/science.8493529 ↗
6. 10.1016/j.biomaterials.2004.02.00210.1016/j.biomaterials.2004.02.002 ↗
7. Regulation of endothelial cell coagulant properties: Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12‐myristate 13‐acetate and tumor necrosis factor10.1016/S0021-9258(19)47120-2 ↗
8. 10.1002/1097-4636(20010905)56:3<376::AID-JBM1106>3.0.CO;2-R10.1002/1097-4636(20010905)56:3<376::AID-JBM1106>3.0.CO;2-R ↗
9. 10.1016/S0142-9612(02)00219-310.1016/S0142-9612(02)00219-3 ↗
10. 10.1002/jbm.a.1032710.1002/jbm.a.10327 ↗
11. 10.1016/j.jvs.2003.08.00710.1016/j.jvs.2003.08.007 ↗
12. 10.1016/S0021-9258(18)34276-510.1016/S0021-9258(18)34276-5 ↗
13. 10.1084/jem.163.3.74010.1084/jem.163.3.740 ↗
14. 10.1084/jem.185.1.15310.1084/jem.185.1.153 ↗
15. 10.1172/JCI11421710.1172/JCI114217 ↗
16. 10.1097/00007890-198510000-0000510.1097/00007890-198510000-00005 ↗
17. 10.1161/01.CIR.93.11.201410.1161/01.CIR.93.11.2014 ↗
18. 10.1161/01.ATV.12.10.111110.1161/01.ATV.12.10.1111 ↗
19. 10.1002/(SICI)1097-4636(19990305)44:3<289::AID-JBM7>3.0.CO;2-O10.1002/(SICI)1097-4636(19990305)44:3<289::AID-JBM7>3.0.CO;2-O ↗
20. 10.1002/(SICI)1097-4636(199711)37:2<176::AID-JBM5>3.0.CO;2-O10.1002/(SICI)1097-4636(199711)37:2<176::AID-JBM5>3.0.CO;2-O ↗
21. 10.1016/S0142-9612(98)00210-510.1016/S0142-9612(98)00210-5 ↗
22. In vivo evaluation of ammonia plasma modified ePTFE grafts for small diameter blood vessel replacement: A preliminary report
23. 10.1002/1097-4636(200102)54:2<272::AID-JBM15>3.0.CO;2-310.1002/1097-4636(200102)54:2<272::AID-JBM15>3.0.CO;2-3 ↗
24. Endothelialization of crosslinked albumin‐heparin gels10.1055/s-0037-1614910 ↗
25. 10.1016/S0142-9612(02)00219-310.1016/S0142-9612(02)00219-3 ↗
26. 10.1016/S0142-9612(98)00167-710.1016/S0142-9612(98)00167-7 ↗
27. 10.4049/jimmunol.163.8.456410.4049/jimmunol.163.8.4564 ↗
28. 10.1097/00005373-200301000-0001410.1097/00005373-200301000-00014 ↗
29. 10.1016/S1074-7613(01)00229-110.1016/S1074-7613(01)00229-1 ↗
30. Monocyte vesiculation is a possible mechanism for dissemination of membrane‐associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide10.4049/jimmunol.153.7.3245 ↗
31. 10.1182/blood.V95.4.1317.004k30_1317_132310.1182/blood.V95.4.1317.004k30_1317_1323 ↗
32. 10.1097/00005373-200203000-0000510.1097/00005373-200203000-00005 ↗
33. 10.4049/jimmunol.161.8.438210.4049/jimmunol.161.8.4382 ↗
34. 10.1002/jbm.a.1037810.1002/jbm.a.10378 ↗
35. 10.1067/mlc.2001.11467710.1067/mlc.2001.114677 ↗
36. 10.4049/jimmunol.163.9.502910.4049/jimmunol.163.9.5029 ↗
37. Cell‐cell interaction and tissue factor expression
38. 10.1016/S0142-9612(02)00543-410.1016/S0142-9612(02)00543-4 ↗